[Prognostic analysis of 62 cases of nasal NK/T-cell lymphoma].
OBJECTIVE
Extranodal NK/T-cell lymphoma of nasal type (ENKTL) is a rare disease entity with unique biological behavior, of which definitive characteristics are still unknown. This study was to investigate the clinical features and prognostic factors of ENKTL in the population of southern China.


METHODS
Records of 62 patients with pathologically confirmed ENKTL, treated in Cancer Center of Sun Yat-sen University from Jan. 1999 to Dec. 2004, were reviewed. Detailed clinical and laboratory data were included in univariate analysis, and statistically significant factors in univariate analysis were then included in multivariate analysis.


RESULTS
Of the 62 patients, 47 were men, and 15 were women, with the median age of 42; 92% of the patients had localized disease, and 76% had international prognostic index (IPI) of 0 or 1. Before treatment, 26% of the patients had anemia, 92% had ECOG performance status (PS) score of 0-1, and 53% presented B symptoms. With a median follow-up duration of 18 months, the median overall survival time was 27 months (95% CI: 10-45 months). In multivariate analysis, hemoglobin (Hb) <110 g/L, B symptoms, and ECOG PS score >1 were statistically significant unfavorable prognostic factors.


CONCLUSIONS
Hb together with B symptoms and PS score may be independent prognostic factors for ENKTL.
Xiao
Jian
J
State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, 510060, P. R. China.
Wang
Shu-Sen
SS
Huang
Yan
Y
Chen
Li-Kun
LK
Guan
Zhong-Zhen
ZZ
Huang
Hui-Qiang
HQ
Xia
Zhong-Jun
ZJ
Xu
Rui-Hua
RH
Lin
Tong-Yu
TY
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D017567:Karnofsky Performance Status; D007694:Killer Cells, Natural; D016399:Lymphoma, T-Cell / Q000097:blood / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009669:Nose Neoplasms / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D011882:Radiotherapy, High-Energy; D012074:Remission Induction; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D006454:Hemoglobins; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone